Diagnostics - US

A Test for prostate cancer – MiCheck® Prostate: quick, non- invasive, highly sensitive and specific

Intended Purpose

MiCheck® Prostate is an algorithm that combines the testing results of three serum immunoassays with the patient’s clinical factors to calculate a MiCheck® Prostate Percentage Risk Score, provides an indication of the likelihood of the presence of aggressive (i.e. clinically significant) prostate cancer (AgCaP) and is called the MiCheck® %Risk of AgCaP. The clinical factors can be included in the algorithm are the patient’s age, result from digital rectal examination (DRE) or a multiparametric MRI (mpMRI)-derived prostate volume result.

MiCheck® Prostate is for male subjects being considered by physicians for a prostate biopsy. It is intended to supplement and not replace the significance of other clinical factors or test results which collectively assist the clinical judgement and experience of the urologist in the decision about whether or not to proceed to prostate biopsy. Prostate biopsy is required for the diagnosis of cancer.

See Minomic Patent Estate and Peer Reviewed Publications.

Get In Touch

14 + 2 =

Privacy Policy

More Info

Would you like to talk with Minomic about:

  • Partnering with us to take our products to your markets?
  • Media or upcoming events?
  • Some feedback that you have?
  • Minomic Internship Program

Suite 2, Ground Floor, 
75 Talavera Road, 
Macquarie Park, NSW 2113, 

International +612 9850 4000
In Australia 02 9850 4000
Compare your time zone with Sydney here

Australian Business Number
14 124 455 081

Copyright © 2024 Minomic®